8-K: The Joint Corp. Reports Mixed Results for 2023, Initiates Refranchising Program

The Joint Corp. announced its fourth quarter and full year 2023 financial results, highlighting revenue growth but also a net loss due to a non-cash valuation allowance and impairment charges, while initiating a refranchising program.

Summary

• The Joint Corp. reported a 16% increase in revenue for 2023, reaching $117.7 million, compared to $101.3 million in 2022.
• System-wide sales grew by 12% to $488.0 million in 2023, while system-wide comparable sales increased by 4%.
• The company experienced a net loss of $9.8 million for the year, primarily due to a $10.8 million non-cash valuation allowance against deferred tax assets and $2.6 million in losses on disposition or impairment.
• Adjusted EBITDA for 2023 was $12.2 million, up from $11.5 million in 2022.
• The company increased its clinic count to 935 by the end of 2023, up from 838 in 2022.
• The Joint Corp. is initiating a refranchising program for the majority of its corporate clinics.
• For the fourth quarter of 2023, revenue grew by 11% to $30.6 million, but the company reported a net loss of $11.0 million.
• The company performed 13.6 million patient visits in 2023, compared to 12.2 million in 2022, and treated 932,000 new patients, up from 845,000 in 2022.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with strong revenue growth and operational improvements offset by a significant net loss and the impact of refranchising efforts. The future outlook is positive but uncertain due to the refranchising program.

Positives

• Revenue increased by 16% year-over-year, reaching $117.7 million.
• System-wide sales grew by 12% to $488.0 million.
• The number of patient visits increased to 13.6 million, up from 12.2 million in the previous year.
• The company treated 932,000 new patients, an increase from 845,000 in 2022.
• Adjusted EBITDA increased to $12.2 million from $11.5 million in the prior year.
• The company's cash position improved significantly, with unrestricted cash at $18.2 million at the end of 2023, compared to $9.7 million at the end of 2022.
• The company has a strong recurring revenue model with 85% of system-wide gross sales from monthly memberships.

Negatives

• The company reported a net loss of $9.8 million for the full year 2023.
• The net loss was primarily due to a $10.8 million non-cash valuation allowance against deferred tax assets and $2.6 million in losses on disposition or impairment.
• Operating loss for the year was $2.1 million, compared to an operating income of $828,000 in 2022.
• The company sold fewer franchise licenses in 2023 (55) compared to 2022 (75).
• The company recorded a net loss of $11.0 million for the fourth quarter of 2023.
• The company's system-wide comp sales growth slowed to 4% in 2023, compared to 9% in 2022.

Risks

• The company faces challenges in identifying and recruiting qualified chiropractors and other personnel due to a nationwide labor shortage.
• Inflation has increased the company's costs and could negatively impact the business.
• The company's refranchising efforts may not be successful or may not generate the expected benefits.
• Short-selling strategies and negative opinions posted online could drive down the market price of the company's stock.
• The company's failure to remediate material weaknesses in internal control over financial reporting could negatively impact its ability to accurately report financial results.
• The timing of corporate clinic sales is uncertain and will impact revenue and Adjusted EBITDA.

Future Outlook

The company expects 2024 system-wide sales to be between $530 and $545 million and system-wide comp sales to be in the mid-single digits. New franchised clinic openings, excluding the impact of refranchised clinics, are expected to be between 60 and 75.

Management Comments

• Peter D. Holt, President and CEO, stated that the company delivered growth in system-wide sales, revenue, Adjusted EBITDA, patient visits, and new patients.
• Management aims to improve top-line growth through increased new patient count and patient engagement.
• The company expects refranchising the majority of corporate clinics to increase the bottom line and cash flow.
• Management believes that actions will create opportunities to reinvest in The Joint and strengthen the health of the franchise network.

Industry Context

The Joint Corp. operates in the chiropractic care market, which is experiencing growth as people seek non-invasive, holistic ways to manage pain. The company is a leader in the industry with a large number of clinics and a strong franchise model.

Comparison to Industry Standards

• The Joint Corp.'s 16% revenue growth in 2023 significantly outpaces the industry's 5-year CAGR of 5.1% as reported by Kentley Insights.
• While specific competitor data is not provided, The Joint Corp.'s system-wide sales growth of 12% and comp sales growth of 4% indicate a strong performance within the chiropractic franchise sector.
• The company's focus on a recurring revenue model with 85% of sales from monthly memberships is a key differentiator compared to traditional chiropractic practices.
• The company's expansion to 935 clinics demonstrates a significant market presence compared to smaller, independent chiropractic offices.

Stakeholder Impact

• Shareholders may be concerned about the net loss but encouraged by the revenue growth and refranchising strategy.
• Franchisees may benefit from the refranchising program and the company's focus on strengthening the franchise network.
• Employees may be affected by the refranchising program and the company's efforts to manage costs.
• Customers will likely see continued access to chiropractic care through the company's network of clinics.

Next Steps

• The company will continue to implement its refranchising program.
• The company will focus on marketing initiatives to drive top-line growth.
• The company will provide guidance on new franchise openings, excluding the impact of refranchised clinics.
• The company will host a conference call to discuss the financial results.

Key Dates

Keywords

chiropractic, franchise, revenue, system-wide sales, EBITDA, refranchising, clinic, patient visits, net loss, marketing